Cryopreservation of hematopoietic progenitor cells

Abstract

Autologous transplantation of hematopoietic progenitor cells requires most of the times the cryopreservation of the hematopoietic progenitor cells (HPC) to maintain their viability until the infusion, which can occur months to years after their collection. Adequate cryopreservation of HPC is realized by submitting the cells to slow freezing velocity (1-3°C/minute) and by employing cryoprotectant agents like the dimethylsulphoxide (Me2SO4), the most used, a colligative agent that reduces the free water content into the cellules and in the extracellular medium. As a consequence, this compound reduces the size and number of ice. The thawing of HPC is done rapidly. The cell suspension can then be infused unmanipulated or  washed to remove Me2SO4 cellular debris and free hemoglobin, potentially toxic both to patients and to cells.